Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

IMI moves forward

Nature Biotechnology volume 29, pages 689–690 (2011)Cite this article

Subjects

To the Editor:

As members of the Governing Board of the Innovative Medicines Initiative (IMI), we wish to respond to two recent articles published in Nature Biotechnology that cast unfounded gloom over IMI1,2.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sinha, G. Nat. Biotechnol. 29, 473 (2011).

    Article  PubMed  Google Scholar 

  2. Editorial. Nat. Biotechnol. 29, 551 (2011).

  3. Abbott, A. Nature 468, 158–159 (2010).

    Article  PubMed  Google Scholar 

  4. Matheis, K.J. et al. Drug Discov. Today (in press).

  5. Obiol-Pardo, C., Gomis-Tena, J., Ferran Sanz, F., Saiz, F. & Pastor, M. J. Chem. Inf. Model. 51, 483–492 (2011).

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Correspondence should be addressed to Michel Goldman, Executive Director, Innovative Medicines Initiative (IMI), Brussels, Belgium. e-mail: michel.goldman@imi.europa.eu

Authors and Affiliations

  1. European Commission, Brussels, Belgium

    Rudolf Strohmeier, Ruxandra Draghia-Akli, Andrzej Rys, Pedro Ortun Silvan & Theodius Lennon

  2. Innovative Medicines Initiative (IMI), Brussels, Belgium

    Rudolf Strohmeier, Ruxandra Draghia-Akli, Andrzej Rys, Pedro Ortun Silvan, Theodius Lennon, Carlo Incerti, Richard Bergström, Salahdine Chibout, Roch Doliveux & Peter Hongaard Andersen

  3. European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium

    Carlo Incerti, Richard Bergström, Salahdine Chibout, Roch Doliveux & Peter Hongaard Andersen

Authors
  1. Rudolf Strohmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruxandra Draghia-Akli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrzej Rys
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pedro Ortun Silvan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Theodius Lennon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carlo Incerti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Richard Bergström
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Salahdine Chibout
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Roch Doliveux
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Peter Hongaard Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

S.C. is with Novartis, R.D. is with UCB, P.H.A. is with Lundbeck and C.I. is with Genzyme.

Additional information

Correspondence should be addressed to Michel Goldman, Executive Director, Innovative Medicines Initiative (IMI), Brussels, Belgium. e-mail: michel.goldman@imi.europa.eu

Rights and permissions

Reprints and permissions

About this article

Cite this article

Strohmeier, R., Draghia-Akli, R., Rys, A. et al. IMI moves forward. Nat Biotechnol 29, 689–690 (2011). https://doi.org/10.1038/nbt.1944

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.1944

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research